MoneyWorks4Me

Jubilant Pharmova jumps on getting USFDA's approval for new Isolator based fill and finish line at Spokane Facility

24 Aug 2026 Evaluate

Jubilant Pharmova is currently trading at Rs. 894.00, up by 14.85 points or 1.69% from its previous closing of Rs. 879.15 on the BSE.

The scrip opened at Rs. 918.70 and has touched a high and low of Rs. 925.95 and Rs. 878.45 respectively. So far 1.48 lakh shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1183.90 on 04-Nov-2025 and a 52 week low of Rs. 783.75 on 10-Mar-2026.

Last one week high and low of the scrip stood at Rs. 925.95 and Rs. 847.75 respectively. The current market cap of the company is Rs. 14,239.73 crore.

The promoters holding in the company stood at 47.68% while Institutions and Non-Institutions held 28.27% and 24.05% respectively.

Jubilant Pharmova has received USFDA’s approval for the commercial batch manufacturing of the first product on the new Isolator based fill and finish line, Line 3 of Jubilant HollisterStier LLC (JHS)’s contract manufacturing facility located in Spokane, WA. U.S.A.

Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma, Singapore, a wholly owned subsidiary of the company.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.

Jubilant Pharmova Share Price

904.00 24.85 (2.83%)
24-Aug-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1909.90
Dr. Reddys Labs. 1194.50
Cipla 1435.00
Lupin 2190.00
Zydus Lifesciences 1101.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: